Description: DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive diagnostic tests to diagnosis skin cancer and related conditions in the United States. The company offers Pigmented Lesion Assay (PLA), a gene expression test that helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. It also provides Nevome test, an adjunctive reflex test for the PLA; and adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. The company is also developing non-melanoma skin cancer diagnostic and non-melanoma skin cancer risk assessment products. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.
Home Page: www.dermtech.com
DMTK Technical Analysis
11099 North Torrey Pines Road
La Jolla,
CA
92037
United States
Phone:
858 450 4222
Officers
| Name | Title |
|---|---|
| Dr. John D. Dobak M.D. | Pres, CEO & Director |
| Mr. Kevin Sun M.B.A. | CFO, Treasurer & Sec. |
| Ms. Claudia Ibarra | Chief Operating Officer |
| Mr. Ray Akhavan J.D. | Gen. Counsel |
| Mr. Todd Michael Wood | Chief Commercial Officer |
| Mr. William W. Zondler | Chief Information Officer |
| Mr. Steve E. Kunszabo | Sr. Director of Investor Relations |
| Ms. Jennifer Eilemberg | Chief Compliance Officer |
| Mr. Ray Bassi | VP of Sales |
| Dr. Burkhard Jansen M.D. | Chief Medical Affairs Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.4347 |
| Price-to-Sales TTM: | 4.3608 |
| IPO Date: | 2017-08-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 255 |